| General Information | |
|---|---|
| ZINC ID | ZINC000049756794 |
| Molecular Weight (Da) | 574 |
| SMILES | O=S(=O)(c1ccccn1)c1ccc(Cl)cc1S(=O)(=O)N1CCC2(CC1)C[C@@H]2NS(=O)(=O)C(F)(F)F |
| Molecular Formula | C19Cl1F3N3O6S3 |
| Action | Antagonist |
| Physicochemical Details | |
|---|---|
| Molar Refractivity | 121.565 |
| HBA | 7 |
| HBD | 1 |
| Rotatable Bonds | 7 |
| Heavy Atoms | 35 |
| LogP | 3.666 |
| Activity (Ki) in nM | 1.585 |
| Polar Surface Area (PSA) | 155.72 |
| Pharmacokinetic Properties (AdmetSAR) | |
|---|---|
| Human intestinal absorption | + |
| Caco-2 | - |
| Blood brain barrier | + |
| P-glycoprotein inhibitior | + |
| P-glycoprotein substrate | - |
| Cyp3a4 substrate | + |
| Cyp2c9 substrate | + |
| Cyp2d6 substrate | - |
| Cyp3a4 inhibition | + |
| Cyp2c9 inhibition | - |
| Cyp2c19 inhibition | + |
| Cyp2d6 inhibition | - |
| Cyp1a2 inhibition | - |
| Acute oral toxicity | - |
| Carcinogenicity (binary) | - |
| Ames mutagenesis | - |
| Human ether-a-go-go-related gene inhibition | - |
| Biodegradation | |
| Glucocorticoid receptor binding | - |
| Thyroid receptor binding | + |
| Androgen receptor binding | + |
| Plasma protein binding | 0.91640245 |
| Pharmacokinetic Properties (SwissADME) | |
|---|---|
| Number of aromatic heavy atoms | 12 |
| Fraction csp3 | 0.42 |
| Ilogp | 1.97 |
| Xlogp3 | 2.87 |
| Wlogp | 6.67 |
| Mlogp | 1.12 |
| Silicos-it log p | 1 |
| Consensus log p | 2.73 |
| Esol log s | -5 |
| Esol solubility (mg/ml) | 5.76E-03 |
| Esol solubility (mol/l) | 1.00E-05 |
| Esol class | Moderately |
| Ali log s | -5.8 |
| Ali solubility (mg/ml) | 9.11E-04 |
| Ali solubility (mol/l) | 1.59E-06 |
| Ali class | Moderately |
| Silicos-it logsw | -6.64 |
| Silicos-it solubility (mg/ml) | 1.32E-04 |
| Silicos-it solubility (mol/l) | 2.31E-07 |
| Silicos-it class | Poorly soluble |
| Pgp substrate | |
| Log kp (cm/s) | -7.76 |
| Lipinski number of violations | 1 |
| Ghose number of violations | 2 |
| Veber number of violations | 1 |
| Egan number of violations | 2 |
| Muegge number of violations | 2 |
| Bioavailability score | 0.55 |
| Pains number of alerts | 0 |
| Brenk number of alerts | 0 |
| Leadlikeness number of violations | 1 |
| Synthetic accessibility | 4.49 |
| Pharmacokinetic Properties (ADMETLab) | |
|---|---|
| Logs | -3.412 |
| Logd | 2.227 |
| Logp | 3.712 |
| F (20%) | 0.002 |
| F (30%) | 0.002 |
| Mdck | 5.86E-05 |
| Ppb | 0.9707 |
| Vdss | 0.561 |
| Fu | 0.0241 |
| Cyp1a2-inh | 0.082 |
| Cyp1a2-sub | 0.241 |
| Cyp2c19-inh | 0.289 |
| Cyp2c19-sub | 0.81 |
| Cl | 1.584 |
| T12 | 0.038 |
| H-ht | 0.968 |
| Dili | 0.997 |
| Roa | 0.034 |
| Fdamdd | 0.985 |
| Skinsen | 0.032 |
| Ec | 0.003 |
| Ei | 0.007 |
| Respiratory | 0.967 |
| Bcf | 0.072 |
| Igc50 | 2.64 |
| Lc50 | 3.264 |
| Lc50dm | 4.505 |
| Nr-ar | 0 |
| Nr-ar-lbd | 0.018 |
| Nr-ahr | 0.035 |
| Nr-aromatase | 0.356 |
| Nr-er | 0.127 |
| Nr-er-lbd | 0.009 |
| Nr-ppar-gamma | 0.01 |
| Sr-are | 0.599 |
| Sr-atad5 | 0.005 |
| Sr-hse | 0.005 |
| Sr-mmp | 0.598 |
| Sr-p53 | 0.008 |
| Vol | 461.808 |
| Dense | 1.241 |
| Flex | 27 |
| Nstereo | 0.259 |
| Nongenotoxic carcinogenicity | 1 |
| Ld50 oral | 1 |
| Genotoxic carcinogenicity mutagenicity | 0 |
| Surechembl | 0 |
| Nonbiodegradable | 0 |
| Skin sensitization | 3 |
| Acute aquatic toxicity | 0 |
| Toxicophores | 2 |
| Qed | 2 |
| Synth | 0.562 |
| Fsp3 | 4.031 |
| Mce-18 | 0.421 |
| Natural product-likeness | 149.111 |
| Alarm nmr | -1.175 |
| Bms | 2 |
| Chelating | 0 |
| Pfizer | 0 |
| Gsk | Accepted |
| Goldentriangle | Rejected |